<DOC>
	<DOCNO>NCT02571140</DOCNO>
	<brief_summary>This study one stage consist multiple treatment visit . The study design assess safety bioavailability Entera 's oral PTH ( 1 - 34 ) adult male healthy volunteer various formulation . The study also design assess reproducibility pharmacokinetic profile various formulation .</brief_summary>
	<brief_title>A Study Assess Safety , Pharmacokinetics Pharmacodynamics Oral PTH ( 1-34 ) Formulations Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Teriparatide</mesh_term>
	<criteria>1 . Signed Informed consent study . 2 . Males , age 18 50 year , BMI 1830 kg/m2 , inclusive , 3 . Subjects able adhere visit schedule protocol requirement 4 . Hematology , Chemistry Urinalysis value clinical significance reflect medical condition accord physician ' judgment might confound result study pose additional risk subject participation study . 5 . Hemoglobin level &gt; 12.5 g/dl 6 . Blood pressure level clinical significance . 7 . Negative serology HIV , Hepatitis B , Hepatitis C. 8 . No known drug alcohol abuse 9 . Negative urinary drug abuse screen 10 . No sensitivity dairy product 11 . No allergy soy bean product . 12 . No prescription medication take within one month enrollment 13 . Overthecounter drug ( include vitamin ) take within 14 day prior visit 2 subject investigator ' discretion inclusion . 14 . No subject previous urolithiasis . 15 . Nonsmoking In good health determine past medical history , physical examination , vital sign , electrocardiogram laboratory test screen 1 . Concurrent therapy , Investigator 's opinion , would interfere evaluation safety efficacy study medication . 2 . Treatment investigational product within last 30 day , enrollment intention enroll active study involve use investigational device drug . 3 . Presence condition circumstance , judgment Investigator , might increase risk patient decrease chance obtain satisfactory data achieve objective study . 4 . Active infection 5 . History drug alcohol abuse 6 . Known allergy sensitivity component study treatment study procedure , include Soy . 7 . Clinically diagnosed psychiatric disorder may interfere patient study participation 8 . Medical history know suspected increase risk AEs relate study drug , investigator 's discretion 9 . Chronic illness , investigator 's discretion</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>